• Author/Authors

    DİRİCAN, Ahmet Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , KÜÇÜKZEYBEK, Yüksel Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , AYDIN, Ayhan Izmir Katip Celebi University - Ataturk Training and Research Hospital, Radiation Oncology Clinic, Turkey , DEMİR, Lutfiye Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , CAN, Alper Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , BAYOGLU, İbrahim Vedat Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , AKYOl, Murat Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , YURTSEVEN, Samim Izmir Katip Celebi University - Ataturk Training and Research Hospital, Radiation Oncology Clinic, Turkey , SOMALİ, İsil Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , ERTEN, Ciğdem Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , ALACACIOĞLU, Ahmet Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey , CAKALAGOĞLU UNAY, Fulya Izmir Katip Celebi University - Ataturk Training and Research Hospital, Pathology Clinic, Turkey , TARHAN, Mustafa Oktay Izmir Katip Celebi University - Ataturk Training and Research Hospital, Medical Oncology Clinic, Turkey

  • Title Of Article

    Induction or Adjuvant Docetaxel/ Cisplatin Chemotherapy in Advanced Stage Non-Metastatic Nasopharyngeal Cancer

  • شماره ركورد
    42133
  • Abstract
    Objective: Meta-analyses of randomized controlled trials was to determine the additional value of induction, concurrent, and/or adjuvant chemotherapy to radiation in the treatment of locally advanced nasopharyngeal carcinoma (NPC) with regard to the overall survival (OS) Material and Methods: A total of 28 patients with loacally advanced NPC were included for this trial. Docetaxel (75 mg/m2 on Day 1) and cisplatin (75 mg/m2 on Day 1) were administered every 21 days, after or before which concurrent chemoradiotherapy (CCRT) was administered. The efficiency of the adjuvant or inductional docetaxel/cisplatin regime and the toxicity profile were retrospectively evaluated Results: The objective response rate (ORR) was 75 % (13 partial responses, 8 complete responses). Stable disease (SD) was seen in 7 patients (25 %) whereas there was no progressive disease (PD). The median PFS for the induction chemoterapy group was 18.7 months and had not been reached for the adjuvant chemoterapy group. The 3-year PFS rates were 20 % and 66,9 %, respectively (p:0.79). The median OS for the induction chemoterapy group was 25.36 months and had not been reached for the adjuvant chemoterapy group. The 3-year OS rate was 26,7 % and 72,2 %, respectively (p:0.231). Conclusion: In our study we demonstrated that the addition of adjuvant chemotherapy to CCRT did not additional benefit compared to hystorical data. Further studies are required to invastigate this hypothesis.r
  • From Page
    92
  • NaturalLanguageKeyword
    Chemotherapy , adjuvant and induction chemotherapy , nasopharyngeal neoplasms
  • JournalTitle
    Kocatepe Medical Journal
  • To Page
    98
  • JournalTitle
    Kocatepe Medical Journal